OALib Journal期刊
X-linked agammaglobulinemia (XLA): Phenotype, diagnosis, and therapeutic challenges around the world
DOI: 10.1016/j.waojou.2019.100018
Ahmed Aziz Bousfiha ,
Alessandro Plebani ,
Alla Volokha ,
Ana Maria Vinet ,
Anna Sediva ,
Anna Shcherbina ,
Antonio Condino-Neto ,
Aydan Ikinciogullari ,
Beata Derfalvi ,
Berta Sanchez ,
Brian Eley ,
Caterina Cancrini ,
Claudio Pignata ,
Ebtihal Kamal ,
Edith Gonzalez Serrano ,
Elham Hossny ,
Farah Naz Qamar ,
Figen Dogu ,
Filomeen Haerynck ,
Ghassan Dbaibo ,
Guiseppe Spadaro ,
Hirokazu Kanegane ,
Irina Abramova ,
J.David M. Edgar ,
Joao Farela Neves ,
John Routes ,
Juan Carlos Aldave ,
Kathleen E. Sullivan ,
Kenneth Paris ,
Liliana Bezrodnik ,
Mikko RJ. Seppanen ,
Mimi Tang ,
Monia Ouederni ,
Nadia Kechout ,
Nelson Rosario ,
Nermeen Galal ,
Nima Rezaei ,
Nita Radhakrishnan ,
Rachida Boukari ,
Rasha Hasan El-Owaidy ,
Rima Hanna-Wakim ,
Roberto Paganelli ,
Sangeetha Siniah ,
Sara Elva Espinosa-Padilla ,
Sonia Qureshi ,
Surjit Singh ,
Tomohiro Morio ,
Viviana Moschese ,
Waleed Al-Herz ,
Yu Lung Lau ,
Zeinab A. El-Sayed Keywords: XLA , Agammaglobulinemia , Infection , Autoimmunity , Outcomes , Immunoglobulin , Therapy CLD , Chronic lung disease , FH , Family history , GI , Gastrointestinal , JIA , juvenile idiopathic arthritis , SCIG , Subcutaneous immunoglobulin , VAPP , Vaccine associated paralytic poliomyelitis , XLA , X-linked agammaglobulinemia
Abstract:
X-linked agammaglobulinemia is an inherited immunodeficiency recognized since 1952. In spite of seven decades of experience, there is still a limited understanding of regional differences in presentation and complications. This study was designed by the Primary Immunodeficiencies Committee of the World Allergy Organization to better understand regional needs, challenges and unique patient features
Full-Text
Please enable JavaScript to view the comments powered by Disqus.
comments powered by
Contact Us
service@oalib.com
QQ:3279437679
WhatsApp +8615387084133
WeChat 1538708413
